Sandia National Laboratories has published an article on the longstanding and productive collaboration between Sandia’s Center for Integrated Nanotechnologies (CINT) and Imagion Biosystems’ R&D scientists.
In accord with ASX requirements, Imagion Biosystems’ 2017 quarterly update was lodged with the Australian Securities Exchange on 31 January 2018. The update includes Appendix
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance